Ustekinumab,vedolizumab
Janssen,Takeda
ustekinumab is associated with reduced risk of serious infection compared to anti-tnf therapy or vedolizumab, but no difference was found in hospitalization or ibd-related surgery. #cccongress23
Our Mission: To cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases.